Five peptide sellers got FDA letters despite 'research use only' labels

On August 24, 2026, the FDA signed warning letters to five online peptide sellers, and posted them on September 1. Every one of the five sold vials labeled "research use only" and "not for human consumption." The agency's position, spelled out letter by letter, is that the label is one sentence and the website is the whole story. It read the whole website.

Who got a letter, and for what

The five are Peak Performance Peptides of Phoenix, Royal Peptides of Boynton Beach, Florida, NuScience Peptides, Peptide Partners, and TXP Innovations, which does business as Tex Peptides. The FDA's published subject line for all of them is "Unapproved New Drugs/Misbranded."

The products named across the letters read like a bestseller list: semaglutide, tirzepatide, retatrutide, SS-31 (also called elamipretide), PT-141 and tesamorelin, plus, according to law-firm summaries of the set, survodutide, mazdutide and ipamorelin blends. Bacteriostatic water appears in several. Royal Peptides' letter also lists a product sold as "BIMORELIN."

The legal machinery is the same in each: the products meet the definition of a drug under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act because of their intended use; they are "new drugs" that were never approved, which violates sections 505(a) and 301(d); and they are not generally recognized as safe and effective under section 201(p). Each company has 15 business days to explain, in writing, what it has done about it.

How the FDA decided these were drugs

None of this turns on chemistry. It turns on intended use, which the FDA reads from everything a seller says and supplies. The letters lay out the evidence in three layers.

First, the copy. Product pages described what the compounds do to a human body, in several cases borrowing figures straight from clinical trials of the approved versions of the same molecules. A sentence about body weight or blood sugar on a product page is, to the FDA, a claim about a drug.

Second, the water. Peak Performance's letter says the company marketed bacteriostatic water "as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration." Royal's letter goes further, citing "bacteriostatic water alongside a peptide guide and peptide calculator, resources that collectively provide the means to prepare an injectable drug for human administration." Selling the powder is one thing; selling the powder, the solvent and the instructions is, in the agency's reading, selling an injection.

Third, the disclaimers, which the letters mention only to set aside. "Research use only" and "not for human consumption" did not offset the rest of the site. The FDA has said this before about supplements and about compounded GLP-1s; this is the first time it has said it this plainly to a group of direct-to-consumer research-peptide storefronts at once.

This isn't new. The net is wider.

The sweep sits on a year of groundwork. In September 2025, the agency sent more than 50 warning letters to companies marketing compounded GLP-1 drugs as "generic versions" of approved products, and opened an import alert on GLP-1 active ingredients with quality concerns. On June 17, 2026, it sent Wholesale Peptide a letter with the same theory. August's five letters extend the pattern from compounders and wholesalers to the storefronts that sell to individuals.

At the same time, the agency is loosening elsewhere. In July 2026, its Pharmacy Compounding Advisory Committee voted to recommend that six peptides be allowed in compounded medicines, a nonbinding recommendation that FDA scientists on the panel argued against, according to reporting from Johns Hopkins. One law firm's headline captured the split: the FDA is balancing peptide policy with enforcement. Compounding by licensed pharmacies may get more room; anonymous vials with a disclaimer are getting less.

What is known, and what isn't

Known: the recipients, the products, the legal theory and the evidence the agency chose to cite. The letters are public and short, and worth reading in full.

Unknown: whether any of the five responded within the 15 days, and what the agency does next. A warning letter is the first step, not the last; seizure, injunction and referral for prosecution are all on the menu if a company keeps going. Also unknown is how the FDA weighs the individual pieces of evidence. The letters describe the totality, not a formula, and a seller that fixed its product copy but kept everything else would be guessing at where the line sits. And the July recommendation is only a recommendation until the agency acts on it, which it has not, as of the sources above.

What this means for researchers

The letters are the clearest map yet of what the FDA reads as intended human use: effect claims lifted from trials, the solvent sold alongside the powder, and guides for putting the two together. For anyone whose work depends on sourcing research material, the practical consequences are about the supply, not the science.

Expect the category to keep tightening. Sellers who survive will be the ones whose sites describe what a material is and how it was tested, not what it does to a person. That is also, not coincidentally, the documentation a researcher needs: identity, purity, lot number, the lab that ran the analysis. A supplier that publishes those is easier to audit and less likely to disappear mid-study.

And treat "research use only" as a description, not a shield. It describes what the material is for. It has never, on its own, settled what a seller intends, and after August it settles even less.